Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 13,349 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intracranial CNS Disorder Clear all
Withdrawn Phase 1 Interventional

PK and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia

NCT05295784
View directory record Official record
Conditions
Acute Kidney Injury, Hypoxic-Ischemic Encephalopathy, Caffeine
Interventions
Caffeine citrate
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
0 Hours to 24 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 4 Interventional Results available

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

NCT04294147
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Erenumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 29, 2026, 11:03 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Diffuse Optical Monitoring With Inhaled Nitric Oxide

NCT03023449
View directory record Official record
Conditions
Stroke
Interventions
Nitric Oxide
Drug
Lead sponsor
Steven Messe
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration

NCT02174848
View directory record Official record
Conditions
Pantothenate Kinase-Associated Neurodegeneration
Interventions
Deferiprone oral solution
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
5 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma

NCT02111785
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Dexamethasone, Burr Hole Craniostomy
Drug · Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

NCT01884740
View directory record Official record
Conditions
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma, Pilomyxoid Astrocytoma, Mixed Oligodendroglioma-Astrocytoma, Brain Stem Glioma, Diffuse Intrinsic Pontine Glioma
Interventions
SIACI of Erbitux and Bevacizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 21 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 29, 2026, 11:03 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

NCT04100889
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Randomized Controlled Trial for Vestibular Treatment in Concussion

NCT03600324
View directory record Official record
Conditions
Vestibular Disorder, Mild Traumatic Brain Injury
Interventions
T-REV
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Colorado Springs, Colorado • Marine Corps Base Camp Lejeune, North Carolina • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Recruiting No phase listed Observational

Delirium Identification in Older Patients With Alzheimer's and Other Related Dementias In the Emergency Department

NCT06326424
View directory record Official record
Conditions
Delirium, Dementia, Hospital Acquired Condition
Interventions
Empatica EmbracePlus
Device
Lead sponsor
Ohio State University
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.

NCT02599259
View directory record Official record
Conditions
Stroke
Interventions
Monitored (M+)
Device
Lead sponsor
AiCure
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 29, 2026, 11:03 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Dry Needling for Spasticity in Stroke

NCT04535479
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Dry Needling
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional Results available

Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor

NCT05012579
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cala Device
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Burlingame, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846
View directory record Official record
Conditions
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions
TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Bexarotene Amyloid Treatment for Alzheimer's Disease

NCT01782742
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

NCT00099242
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Alzheimer Type
Interventions
rivastigmine transdermal patch
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Selective Versus Routine Shunting in Carotid Endarterectomy Patients

NCT00967486
View directory record Official record
Conditions
Stenoses, Carotid Artery
Interventions
Carotid endarterectomy with routine shount, Carotid endarterectomy with selective shunt
Procedure
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Recruiting No phase listed Observational

Natural History Study of Synucleinopathies

NCT01799915
View directory record Official record
Conditions
Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder, Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Shy-Drager Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Not listed Not applicable Interventional

The Effect of Combined Armeospring and CIT on Neuro-motor and Functional Recovery in Children With Unilateral CP

NCT02914925
View directory record Official record
Conditions
Cerebral Palsy, Hemiplegia, Upper Extremity Weakness
Interventions
ArmeoSpring/CIT
Device
Lead sponsor
St Mary's Hospital for Children
Other
Eligibility
7 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional

A Study of Decreased Mental Function Associated With HIV

NCT00027040
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
Selegiline hydrochloride
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

NCT02100150
View directory record Official record
Conditions
Concussion
Interventions
NNZ-2566, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
16 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE

NCT03635450
View directory record Official record
Conditions
Moderate to Severe Hypoxic-ischemic Encephalopathy
Interventions
Infusion of hCT-MSC
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
0 Hours to 48 Hours
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional

Neurosurgical Use of Interstitial Laser Therapy (ILT)

NCT00207350
View directory record Official record
Conditions
Brain Tumor
Interventions
Interstitial Laser Therapy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

NCT04969497
View directory record Official record
Conditions
Migraine
Interventions
Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

NCT00118924
View directory record Official record
Conditions
Tick-Borne Encephalitis
Interventions
LGT(TP21)/DEN4, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2008 · Synced Oct 29, 2026, 11:03 AM EDT